Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa

Shiha, Gamal; Alswat, Khalid; Khatry, Maryam Al; Sharara, Ala I.; Örmeci, Necati; Waked, Imam; Benazzouz, M.; Al-Ali, Fuad; Hamed, Abd Elkhalek; Hamoudi, Waseem; Attia, Dina; Derbala, Moutaz; Sharaf-Eldin, Mohamed; Al-Busafi, Said A.; Zaky, Samy; Bamakhrama, Khaled; Ibrahim, Nazir; Ajlouni, Yousef; Mériam, Sabbah; Salama, Mohsen; Anushiravani, Amir; Afredj, Nawel; Barakat, Salma; Hashim, Almoutaz; Fouad, Yasser; Soliman, Reham

doi:10.1016/s2468-1253(20)30213-2

Cited by 125 publications

(112 citation statements)

References 40 publications

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…The recent landmark articles by Eslam et al 1,2 have attracted substantial attention from various stakeholders. [3][4][5][6][7][8][9] although concerns have been raised that such a change may lead to confusion, particularly among non-hepatologists. 10 To better assess physician awareness, perception of disease severity, patterns of practice for the diagnosis and management of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and to determine the impact of the proposed change in nomenclature, we undertook a national faceto-face survey from November 20, 2020 to December 20, 2020.…”

Section: To the Editormentioning

confidence: 99%

Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists

Fouad

Gomaa

Semida

et al. 2021

Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists

Fouad

Gomaa

Semida

et al. 2021

Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

“…Following pioneer attempts, several authors have proposed to rename NAFLD, the most recent of such proposals resulting in the definition of this disease as MAFLD, i.e., metabolic (dysfunction)-associated fatty liver disease, which aims at emphasizing the strong connections of NAFLD with diabetes and obesity in most individuals [15,16]. Although the initiative to rename NAFLD to MAFLD has generally been welcomed by the scientific community [17][18][19], the suggestion to change the name has been felt to contain some elements of prematurity and a debate is presently ongoing [20,21].…”

Section: Introductionmentioning

confidence: 99%

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Lonardo¹,

Arab

Arrese

2021

Adv Ther

View full text Add to dashboard Cite

Precision medicine defines the attempt to identify the most effective approaches for specific subsets of patients based on their genetic background, clinical features, and environmental factors. Nonalcoholic fatty liver disease (NAFLD) encompasses the alcohol-like spectrum of liver disorders (steatosis, steatohepatitis with/without fibrosis, and cirrhosis and hepatocellular carcinoma) in the nonalcoholic patient. Recently, disease renaming to MAFLD [metabolic (dysfunction)-associated fatty liver disease] and positive criteria for diagnosis have been proposed. This review article is specifically devoted to envisaging some clues that may be useful to implementing a precision medicine-oriented approach in research and clinical practice. To this end, we focus on how sex and reproductive status, genetics, intestinal microbiota diversity, endocrine and metabolic status, as well as physical activity may interact in determining NAFLD/ MAFLD heterogeneity. All these factors should be considered in the individual patient with the aim of implementing an individualized therapeutic plan. The impact of considering NAFLD heterogeneity on the development of targeted therapies for NAFLD subgroups is also extensively discussed.

show abstract

“…In addition, the new name and definition has received the support and endorsement from multiple stakeholders, including patients, patient advocacy associations, nurses and allied health leaders, indicating that a broad consensus is emerging. [9][10][11] Beyond this, the trajectory of evidence supporting the utility of the definition in practice continues to be forthcoming. 12 The MAFLD criteria identifies patients with more advanced hepatic fibrosis, 13 incident cardiovascular disease, 14 chronic kidney disease, 12,15 and those who would benefit from an assessment of genetic risks for fatty liver 16,17 better than the old criteria.…”

Section: Mafld: Now Is the Time To Capitalize On The Momentummentioning

confidence: 99%